In the BIOSTORM study, neither p-ERK, p-VEGFR2, nor VEGFA copy number status was significantly correlated with recurrence prevention by sorafenib [9], suggesting that the mechanisms of action of the drug and tumor biology in response to therapy are more complex than previously understood. This evidence concerns the gene VEGFA and neoplasm.